BACKGROUND: Published guidelines regarding the optimal treatment strategies for brain metastases focus on patients with 3 lesions. As delivery techniques for stereotactic radiosurgery (SRS) improve, radiation oncologists are increasingly using it for patients with >3 metastases. In the current study, the authors sought to characterize practice patterns among practitioners to identify areas of controversy. METHODS: A survey of practicing radiation oncologists was distributed via e-mail. Responses were collected from April 1 to May 5, 2016. Survey data were analyzed. RESULTS: A total of 711 currently practicing radiation oncologists responded, for a response rate of 12.5%. Specialists in central nervous system tumors (CNS specialists) were more likely to treat higher numbers of patients with brain metastases with SRS. There was a significant difference in the optimal "cutoff number" used when deciding how many lesions to treat with SRS versus whole-brain radiotherapy. Cutoff numbers were significantly higher for high-volume CNS specialists (10 patients/month) than for either low-volume CNS specialists (5-9 patients/month) or high-volume, non-CNS specialists (8.1 vs 5.6 and 5.1, respectively; P<.001). A majority of respondents (56%) identified patients with 4 to 6 brain metastases as being the most challenging patients to treat. CONCLUSIONS: To the authors' knowledge, there appears to be no consensus regarding the optimal treatment strategy among patients with >3 brain metastases, and practice patterns are heterogeneous. Radiation oncologists, especially high-volume CNS specialists, are treating significantly more brain metastases with SRS than what currently is recommended by published consensus guidelines. Providers struggle with patients with a moderate intracranial disease burden. Further prospective studies are needed to support these practice patterns and guide decision making. Cancer 2017;123:2274-82.
INTRODUCTION
Brain metastases are a common problem facing oncologists, appearing in an estimated 20% to 40% of patients with cancer. 1 As systemic therapies improve and patients live longer with metastatic disease, the interest in improving the management of this patient population has grown considerably, with a focus on balancing quality of life and achieving durable intracranial control. Several systematic reviews and guidelines have been published on the topic. [1] [2] [3] [4] There are numerous management strategies for brain metastases, including various permutations of surgery, stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and hippocampal-sparing WBRT (hsWBRT). Consensus guidelines such as those published by the National Comprehensive Cancer Network 5 currently are limited in scope, and in the majority of cases these modalities can be used at the discretion of the practitioner.
The guidelines published to date are detailed and instructive for patients with up to 3 to 4 brain metastases. 1, 3, 5 However, as SRS techniques improve and providers become more experienced, there has been a proclivity to treat increasing numbers of brain metastases with SRS. [6] [7] [8] WBRT is associated with significant cognitive side effects, 9 and many providers are reluctant to recommend this treatment to otherwise healthy patients. Anecdotally, there are regional and institutional differences in the treatment of brain metastases with regard to dose used, use of SRS, and when to use WBRT. There also is emerging interest in hsWBRT due to recently published data demonstrating improved neurocognitive outcomes with this technique. 10 In this rapidly developing landscape of treatment options, it may be daunting for clinicians to choose an optimal management strategy for patients. Assessing current practice helps oncologists to recognize trends in the field and identify areas in need of further investigation. Furthermore, recent studies have shown a clear link between practice volume and patient outcomes in the setting of radiation for high-risk prostate cancer, 11 head and neck cancer, 12 and non-small cell lung cancer. 13 Thus, we sought to investigate the relationship between provider characteristics and treatment decision making in the setting of RT for brain metastases by querying a large sample of currently practicing radiation oncologists. Prior surveys regarding practice patterns for brain metastases have been limited in scope, 14 and to our knowledge there have not been similar surveys detailing the relationship between provider characteristics and practice patterns. We hypothesized that characteristics such as specialization in central nervous system (CNS) lesions, practice setting (academic vs nonacademic), and volume of patients with brain metastases would impact the use of SRS.
MATERIALS AND METHODS

Survey Design and Deployment
The survey was designed to identify trends in clinical practice regarding patients with brain metastases among currently practicing radiation oncologists. To capture contemporary practice ethos, we queried all non-membersin-training in the membership directory of the American Society for Radiation Oncology. A total of 5688 physicians were contacted by e-mail and invited to complete our survey, which was hosted by Research Electronic Data Capture (REDCap). 15 The survey was comprised of 33 questions. All participants who completed the survey were automatically entered into a drawing to win 1 of 10 gift cards worth $50 each. The survey contained screening questions to ensure that respondents were practicing radiation oncologists, not currently in training, and actively treating patients with brain metastases. A series of demographic questions determined practice and provider characteristics. We provided several clinical patient scenarios in which respondents were asked to choose their treatment of choice from several options. To get a more quantitative sense of the maximum number of brain metastases currently being treated with SRS, we asked respondents to enter an ideal "cutoff number," which represents the number at which they would switch from using SRS to WBRT. The survey also contained questions regarding the dose used for SRS and WBRT, as well a question asking which group of patients presents the greatest challenge. A copy of the survey is available in the Supporting Information.
Cutoff Numbers
For patient scenario questions, respondents were asked to choose management strategies for a variety of patients with differing numbers of brain metastases. The number of metastatic lesions chosen for each scenario was informed based on available guidelines, 1, 3 as well as retrospective and observational studies. [6] [7] [8] This was done with the objective of assessing how respondents interpreted and used the available data in their decision-making process.
Statistical Analysis
Before analyses, descriptive statistics (eg, frequencies and percentages) were used to characterize the participant sample. Generally, analyses were descriptive; however, comparisons were made: 1) between subgroups of radiation oncologists working in academic and nonacademic settings; 2) between CNS specialists and non-CNS specialists; and 3) high-volume versus low-volume practitioners for cases referred for patients with brain metastases. Two-sample tests such as Student t tests, chi-square tests, and Fisher exact tests were used as appropriate. In addition, we used a negative binomial regression model to examine associations between the "cutoff number" and the grouping variables described above. All main effects and 2-way interactions between predictors were entered into the model and backwards elimination of variables with a P > .2 was used as a model selection strategy. All data analyses were completed using R statistical software (version 3.2.5; R Foundation, Vienna, Austria) and a P value < .05 was considered to be statistically significant.
RESULTS
Response Rate and Demographics
There were 711 responses (response rate of 12.5%). Of these, 678 respondents were currently practicing nonmembers-in-training and were included in the analysis. Reasons for exclusion included not currently practicing (15 respondents), initiating the survey but not answering any questions (10 respondents), not treating brain metastases (7 respondents), and still being in training (1 respondent). A total of 627 respondents completed the survey, and the remaining 84 responses were partially complete. All useable information was included. A summary of respondent characteristics is presented in Table 1 . Detailed responses for percentage of patients treated with brain metastases and SRS technology are available in the online Supporting Information Tables S1 and S2.
Clinical Scenarios
Respondents were given a series of clinical scenarios involving patients with brain metastases and asked to choose between management options. Providers were asked to assume that the patient had been seen by neurosurgery and a form of RT had been recommended. Patients were assumed to have newly diagnosed intracranial disease; lesions measuring < 3 cm in size; and a primary tumor that was not of small cell, leukemia, lymphoma, or germ cell histology. The results are presented in Figure 1 . Respondents who specialized in CNS tumors (CNS specialists) more frequently chose to use SRS or a combination of SRS and WBRT compared with non-CNS specialists.
The survey then asked for providers to choose one of the same management strategies for a series of special scenarios, such as retreatment or the development of progressive extracranial disease. In addition to the assumptions above, patients were assumed to have a Karnofsky performance status (KPS) score > 70. The results are presented in Figure 2 . Again, CNS specialists were found to be more likely to treat these patients with SRS, even within the setting of prior RT or uncontrolled extracranial disease.
Cutoff Number
Respondents were asked to enter a number representing their "cutoff number" of metastases when choosing SRS versus WBRT for a lesion measuring <3 cm in a patient with good KPS. A regression model was used to examine associations between the cutoff number and the type of practice (academic vs nonacademic), specialization (CNS specialist vs not), and the number of monthly CNS patients. An interaction between specialization and the number of patients emerged, such that among CNS specialists, the cutoff number increased with increasing number of patients treated per month, but this trend was not observed among non-CNS specialists (Fig. 3 ). Providers were defined as having minimal volume (0-4 patients per month), low volume (5-9 patients per month), or high volume (10 patients per month). The predicted cutoff numbers among minimal volume, low-volume, and highvolume CNS specialists were 4.1, 5.6, and 8.1 patients per month, respectively (incremental P values of .057 and <.001). It is interesting to note that among non-CNS specialists, the cutoff numbers did not vary by practice volumes and were 5, 5.2, and 5.1 patients per month, respectively (P 5 .4 and .8). The difference in the cutoff number between high-volume specialists and nonspecialists was statistically significant (P < .001). The type of practice (academic vs nonacademic) did not appear to impact the cutoff number.
The cutoff number also was compared between US-based providers versus non-US-based providers, the number of years since the completion of training, and access to Gamma Knife or CyberKnife. The difference was found to be significantly different between US-based providers and non-US-based providers (5.5 vs 4.7, respectively; P 5 .005). There was no difference noted based on the number of years since the completion of training (P 5 .57). Providers with access to Gamma Knife or CyberKnife were found to have a higher cutoff number compared with providers with access to linear accelerator (LINAC)-based SRS only (6.6 vs 4.8, respectively; P<.001) (see Supporting Information Table S3 ).
Decision-Making Factors
To ascertain the relative importance of patient characteristics when choosing a treatment option, respondents were asked to rank potentially important factors when deciding between WBRT and SRS for patients with newly diagnosed brain metastases. Choices included the number of lesions, size of the lesions, extracranial disease status, KPS, histology, and convenience to the patient. Providers most often chose "number of lesions" as the most important factor and "convenience to the patient" as the least important. A graph representing these results is presented in Figure 4 . The rankings for each individual factor are provided in Supporting Information Figure S1 .
Treatment Dose
Respondents were asked to choose their typical SRS dose for the treatment of a patient with a single subcentimeter brain metastasis in a noneloquent area. The most commonly chosen answer (41% of respondents) was 20 to 22 grays (Gy). Approximately 23% of respondents chose 18 to 20 Gy, and 23% chose > 22 Gy. Only 8% and 5% of respondents, respectively, chose 16 to 18 Gy or < 16 Gy. There was no association noted between the dose used and specialization (P 5 .9), patient volume (P 5 .2), or academia (P 5 .9).
Respondents were asked what dose and fractionation they would use when delivering WBRT to patients with good KPS. The most common choice (66% of respondents) was 30 Gy in 10 fractions. The next most common selection was 37.5 Gy in 15 fractions (26% of respondents). Less than 5% of providers chose other regimens, which included 20 Gy in 5 fractions or 40 Gy in 20 fractions, among others.
Hippocampal Sparing
The most common scenario in which hsWBRT was chosen was for a patient with good KPS and 9 newly diagnosed brain metastases (73 providers; 11% of respondents). Similarly, a noteworthy percentage of providers (9%) chose hsWBRT for a patient with good KPS and 15 newly diagnosed brain metastases. The number of providers choosing hsWBRT was found to drop significantly when considering patients with the same number of metastases but poor KPS (5% and 3% of respondents, respectively, for 9 and 15 lesions). Respondents were significantly more likely to choose hsWBRT in patients with good KPS compared with those with poor KPS. When averaging across the available scenarios, 5.3% of respondents chose hsWBRT for patients with high KPS versus 2.9% for patients Figure 2 . Special patient scenarios. Each bar represents a patient with the characteristics listed beneath it. Segments represent the percentage of providers (segregated by central nervous system [CNS] specialists vs non-CNS specialists) who chose to treat the patient with each modality. Statistically significant differences are noted as follows: ** indicates P<.01 and ***, P<.001. All patients were assumed to have a Karnofsky performance status score >70. The lesions were assumed to all measure <3 cm and not be of small cell, leukemia, lymphoma, or germ cell origin. SRS indicates stereotactic radiosurgery; WBRT, whole-brain radiotherapy.
with low KPS (odds ratio, 1.85; 95% confidence interval, 1.39-2.46).
Provider Challenges
A question was posed that required choosing which group of patients is most challenging when making treatment decisions. Of 615 respondents, a majority (342 respondents; 56%) chose patients with 4 to 6 metastases. The next most selected group (107 respondents; 17%) was patients with 7 to 9 metastases. The responses were compared between academic versus nonacademic providers, CNS specialists versus non-CNS specialists, and high-volume practice versus low-volume practice and minimal volume practice respondents, and there were no significant differences noted.
Neurosurgery Involvement
Providers were asked to describe the involvement of neurosurgery in their SRS workflow. The overall response rates are presented in Table 1 . Academic providers were more likely to have neurosurgery involvement versus nonacademic providers. Approximately 57% of academic providers reported neurosurgery involvement in all SRS cases, 28% reported it in selected SRS cases, and 15% reported it in no cases. Conversely, 34% of nonacademic providers reported neurosurgery involvement in all SRS cases, 43% reported it in selected SRS cases, and 23% reported it in no cases (P<.001).
DISCUSSION
To our knowledge, there is minimal controversy regarding the management of patients with brain metastases at the extreme ends of the spectrum. There is high-level evidence supporting the use of SRS in a patient with good performance status and a small solitary brain metastasis. 9, [16] [17] [18] Similarly, few would argue for the use of SRS in a patient with innumerable brain metastases. However, in a patient with excellent performance status and a moderate brain metastasis burden, the decision-making process is more nuanced and data guiding physicians and treatment decisions are lacking. With advances in radiation technologies and new systemic therapies demonstrating effective control of intracranial disease, 19, 20 the role of SRS is evolving beyond the treatment of 1 to 3 lesions. The data from the current study not only reflect this trend, but also expose the heterogeneity in practice patterns and suggest that CNS specialists are leading the field in the expanding use of SRS. Nevertheless, to the best of our knowledge, there currently is a paucity of evidence demonstrating the improved efficacy or safety of various treatment approaches (SRS, WBRT, or hsWBRT) in these controversial areas.
Recently published studies have explored management strategies in challenging groups of patients, such as those with a moderate number of brain metastases or those requiring retreatment. A retrospective study published in 2012 examined 61 patients with 10 brain metastases who underwent SRS. 8 The majority of patients in this study (54 of 61 patients) had received prior treatment either with SRS, WBRT, or both. The authors noted several factors that contributed to a shorter survival in patients treated with SRS, including having 14 brain metastases, melanoma histology, uncontrolled extracranial disease, worse KPS, and a lower recursive partitioning analysis class. The authors concluded that SRS was a safe and effective treatment for patients with 10 brain metastases, and may be most effective for patients without the adverse prognostic factors they discovered. These findings generally are in agreement with practice patterns we found in the current study: providers are more reluctant to treat patients with SRS who have higher numbers of lesions, low KPS, or progressive extracranial disease. Very few respondents answered that they would use SRS for patients with 15 lesions, even in a patient with good KPS (Fig. 1) . Curiously, the majority of providers would treat 2 brain lesions with SRS in a patient with uncontrolled extracranial disease, but if the same patient had 5 lesions the number dropped significantly (Fig. 2) . We could not find evidence in the literature to support one or the other treatment approaches. It is possible that this finding reflects providers using the more conservative currently published guidelines of treating 3 lesions with SRS when dealing with a patient with uncontrolled extracranial disease. More recently, 2 studies from Japan further investigated the use of SRS among patients with a moderate intracranial metastatic disease burden. The first was a retrospective cohort study comparing the outcomes of patients who had received SRS for 2 to 9 brain metastases with the outcomes of patients with 10 lesions. 6 In their propensity-matched analysis, there were no significant differences found with regard to overall survival, neurological death, neurological deterioration, or SRS-related complications between the 2 groups. The second was a multi-institutional, prospective observational study that used SRS to treat patients with good performance status with 1 to 10 newly diagnosed brain metastases measuring <3 cm in diameter. 7 Overall survival was found to be better in patients with a solitary brain metastasis but did not differ between those with 2 to 4 compared with 5 to 10 metastases. There was no difference in radiosurgeryrelated adverse events noted between the groups. There also was no difference in the use of salvage SRS or WBRT between groups. This study provided further evidence that SRS is likely acceptable for patients with 4 to 10 lesions. It is important to note that these studies did not directly evaluate the cognitive impact of using SRS versus WBRT in the setting of a patient with a moderate CNS burden.
The present study echoes the unanswered questions from the studies above, namely how many brain metastases can we safely and effectively treat with SRS, and what other clinical factors should impact that number? In the current study, we used clinical scenarios to tease out what kinds of patients are commonly being treated with SRS. We found that the majority of practitioners, regardless of practice setting, are treating patients with a single brain metastasis or 3 brain metastases with SRS, which is consistent with current guidelines. Similarly, WBRT is commonly used in patients with 9 or 15 brain metastases, especially within the setting of a poor performance status. Even this pattern of practice is evolving, with interim results from the Medical Research Council QUARTZ trial demonstrating no benefit in quality of life or overall survival in patients with lung cancer with brain metastases who are treated with WBRT versus supportive care when the treating physician and patient were uncertain of the benefit of WBRT. 21 We hypothesized that an academic versus nonacademic practice setting would impact the use of SRS. However, we found instead that CNS specialization and patient volume were the drivers of decision making. These results may be impacted by the contribution of experienced nonacademic CNS specialists such as those working at free-standing CyberKnife or Gamma Knife centers who frequently treat high numbers of brain metastases. There also may be academicians who are CNS specialists but either are more research-oriented or focus primarily on other CNS pathologies such as gliomas and infrequently treat patients with brain metastases. It is important to note that we found that CNS specialists are consistently more likely to treat a higher number of metastases with SRS. When asked to provide a cutoff number for switching from SRS to WBRT, CNS specialists gave a significantly higher number than non-CNS specialists (8.1 vs 5.1 among high-volume providers). In addition, among CNS specialists, those who treat higher numbers of patients with brain metastases were found to have a significantly higher cutoff number than those who treat these patients less frequently (8.1 in high-volume providers vs 5.6 in low-volume and 4.1 in minimal volume providers). This exposes an interesting heterogeneity in patterns of care, some of which may not be supported by current evidence. Patients with brain metastases are likely to receive different treatments depending on what type of radiation oncologist they see, and those who are seen in academic centers are more likely to have neurosurgery involvement in their SRS treatment. As in many areas of medicine, specialists are on the forefront of modern technology and tend to be the providers Original Article who are practicing outside the bounds of current treatment guidelines. It is interesting to note that the majority of non-CNS specialists, regardless of patient volume, consistently reported a cutoff number of approximately 5. This number does not reflect any published guidelines, but perhaps it more accurately represents the minimum comfort level of currently practicing radiation oncologists.
When asked which group of patients was most challenging when making treatment decisions, the majority of providers chose those with 4 to 6 brain metastases. This finding underscores once more that providers are mostly struggling with patients with a moderate brain metastasis burden. The studies cited above indicate that indeed it may be safe and effective to treat patients with 4 to 6 or even 10 brain metastases with SRS; however, a significant number of these patients still are being treated with WBRT. Despite these studies demonstrating the safety and efficacy of SRS among this population, current practice guidelines shy away from recommending SRS for patients with >3 metastatic lesions. Therefore, patients with multiple brain metastases may experience more innovative treatment approaches when presenting to a CNS specialist practicing at a high-volume center given that their practice patterns are more reflective of the emerging literature.
The current study has several limitations, including those inherent to all survey studies. Although > 600 actively practicing providers completed our survey, a majority of providers did not, thereby introducing the possibility of nonresponse bias. However, data have suggested that response rates and bias are not necessarily correlated, 22, 23 and question the impact of this in physician surveys. [24] [25] [26] Furthermore, we intentionally targeted a large group of physicians to maximize the absolute number; it is quite possible that some of the physicians who received the survey do not routinely use SRS, and thus our practical response rate is likely significantly higher than this nominal response rate. Responses were multiple choice and may not capture the full range of provider opinions. Survey fatigue also can result in responses that are not genuine. In addition, we did not assess how different regional insurance carriers affect providers' treatment decisions, nor did we fully evaluate differences in patterns between US-based and non-US-based providers because the majority of respondents were US-based. We also did not address the rapidly evolving topic of targeted systemic agents in patients with brain metastases. This is an important limitation because the emergence of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is likely impacting the management of patients with brain metastases. These agents effectively penetrate the bloodbrain barrier, 27 and are reported to have response rates of up to 88% in prospective studies evaluating their upfront use in patients with brain metastases from adenocarcinoma. 28 Intracranial progression rates while receiving EGFR TKI therapy range from 61% to 81%, 28, 29 thereby highlighting the continued relevance of local therapies such as RT. However, next-generation EGFR TKI agents that have been specifically designed to cross the bloodbrain barrier have demonstrated promising early results. 30 In addition, newer targeted agents have shown very promising results in CNS penetration in the setting of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer, 31, 32 and in progression-free and overall survival in patients with BRAF-mutated melanoma. 33 Targeted therapies also have been shown in retrospective series to improve overall survival when used in patients who have previously received cranial RT. 34 As more data from these agents emerge, their use will undoubtedly expand, and they may be able to delay or obviate the need for WBRT in selected patients, such as those with multiple, small, asymptomatic brain metastases. They also would be valuable in the setting of multiple recurrent brain metastases in patients who have already received WBRT.
This study summarizes the current heterogeneous practice patterns and decision-making processes among radiation oncologists who treat patients with brain metastases. Radiation oncologists, especially CNS specialists, appear to be confident in treating many more brain metastases with SRS than what is currently recommended by published consensus guidelines, despite a lack of clear evidence for this practice. In general, providers struggle the most with patients with a moderate intracranial disease burden. Further prospective studies are needed to support this emerging practice pattern and better guide decision making.
